3rd Annual Emerging Paradigms in Liver Cancer Diagnosis and Treatment

Add to Calendar 3rd Annual Emerging Paradigms in Liver Cancer Diagnosis and Treatment 3/14/2026 7:30:00 AM 3/14/2026 3:30:00 PM America/New_York For More Details: https://umich.cloud-cme.com/course/courseoverview?EID=81982 Description: We are happy to host the 3rd Annual Emerging Paradigms in Liver Cancer Diagnosis and Treatment this year at the JW Marriott in Grand Rapids and virtually. The full-day conference will focus on the full spectrum of primary liver cancers, from early detection, diagnosis, to novel cutting-edge treatments. The program will feature University of Michigan faculty members and external speakers, with ample op... Hybrid false MM/DD/YYYY


Date & Location
Saturday, March 14, 2026, 7:30 AM - 3:30 PM ET, Hybrid, Grand Rapids, MI

Target Audience
Specialties - Gastroenterology, Hematology/Oncology, Hepatology, Medical Oncology, Pathology, Radiation Oncology, Surgery, Transplant Surgery
Professions - House Officer, Medical Student, Nurse, Nurse Practitioner, Other Healthcare Professional, Physician, Physician Assistant, Physician Fellow, Physician Resident

Credits
AMA PRA Category 1 Credits™ (5.50 hours), Non-Physician Attendance (5.50 hours)

Overview
We are happy to host the 3rd Annual Emerging Paradigms in Liver Cancer Diagnosis and Treatment this year at the JW Marriott in Grand Rapids and virtually. The full-day conference will focus on the full spectrum of primary liver cancers, from early detection, diagnosis, to novel cutting-edge treatments. The program will feature University of Michigan faculty members and external speakers, with ample opportunities for discussion and interactions.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Identify patients who are appropriate candidates for liver cancer surveillance.
  2. Select and utilize effective surveillance methods to enhance early detection of hepatocellular carcinoma.
  3. Apply appropriate risk stratification and treatment strategies for hepatocellular carcinoma and cholangiocarcinoma, as well as understanding the current clinical trial pipeline for liver cancer therapies.
  4. Explain emerging treatment options for liver cancer and understand how these therapies are sequenced in clinical practice.

Accreditation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AMA PRA Category 1 
The University of Michigan Medical School designates this Live Activity for a maximum of 5.50 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Additional Information

Accessibility Statement
 
The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.

Questions? Please contact [email protected] or call (734) 936-7093.


Keywords: LIVEAMAFeatured